Skip to main content
. Author manuscript; available in PMC: 2014 May 12.
Published in final edited form as: Clin Pharmacol Ther. 2012 Sep 26;92(5):661–665. doi: 10.1038/clpt.2012.164

Table 2.

Substrate-dependent IC50 or Ki values for inhibition of hOCT2 by cimetidine (data from [35] and our laboratories).

Cimetidine
Ki/IC50 (µM)
Substrate Substrate concentration
(µM)
Reference
14 Amil 1 [62]
36 ASP 1 [63]
23 ASP 20 [44]
26 ASP 1 [62]
27 Crea 5 [64]
1380 Et 1 [57]
510 Met 10 [65]
110 MPP 0.01 Unpublished
142 MPP 15 Unpublished
120 MPP 0.01 [58]
70.4 NBD-MTMA 10 Unpublished
70 TEA 5 [17]

Amil = Amiloride, ASP = 4-(4-(dimethylamino)styryl)-N-methylpyridinium, Crea = Creatinine, Et = ethidium, Met = metformin, MPP = 1-methyl-4-phenylpyridinium, NBD-MTMA = [2-(4-nitro-2,1,3-benzoxadiazol-7-yl)aminoethyl]trimethylammonium, TEA = tetraethylammonium. Bold = molecules highlighted to show for the same probe substrate the comparable IC50 or Ki